XML 62 R52.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaborative Agreements (Details) |  |  |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | --- | --- | --- | --- | ---
Apr. 11, 2018 USD ($) | Dec. 31, 2017 USD ($) | Dec. 29, 2017 | Aug. 07, 2015 product | Mar. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Feb. 28, 2017 USD ($) | Sep. 30, 2015 USD ($) | Apr. 30, 2015 USD ($) | Sep. 30, 2013 USD ($) | Sep. 30, 2018 USD ($) | Sep. 30, 2017 USD ($) | Sep. 30, 2018 USD ($) | Sep. 30, 2017 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  | $ 2,000,868 | $ 2,644,543 | $ 27,979,273 | $ 33,432,852
Revenue recognized |  |  |  |  |  |  |  |  |  |  | 316,000 |  | 1,300,000 |
Deferred grant funding |  | $ 0 |  |  |  | $ 0 |  |  |  |  | 1,297,416 |  | 1,297,416 |
ApolloBio |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  | 0 |  | 23,000,000 |
Deferred revenue |  | 0 |  |  |  | 0 |  |  |  |  | 0 |  | 0 |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  | 23,000,000 |
MedImmune |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  | 1,800,000 |  | 4,500,000 |
Deferred revenue |  | 1,145,500 |  |  |  | 1,145,500 |  |  |  |  | 295,533 |  | 295,533 |
Accounts receivable |  | 1,693,530 |  |  |  | 1,693,530 |  |  |  |  | 2,352,323 |  | 2,352,323 |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  | 1,582,167 |
Collaborative Arrangement, Product | ApolloBio |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Territory expansion option period |  |  | 3 years |  |  |  |  |  |  |  |  |  |  |
Proceeds received in upfront payment |  |  |  |  | $ 19,400,000 |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  | 23,000,000 |  |  |  |  |  | 23,000,000 |  |  |
Advisory fees |  |  |  |  | 960,000 |  |  |  |  |  |  |  |  |
Additional revenue to be achieved |  |  |  |  |  |  |  |  |  |  |  |  | $ 20,000,000 |
Royalty period |  |  |  |  |  |  |  |  |  |  |  |  | 10 years |
Period from effective date for termination |  |  |  |  |  |  |  |  |  |  |  |  | 1 year |
Number of days written notice before termination |  |  |  |  |  |  |  |  |  |  |  |  | 90 days |
Collaborative Arrangement, Product | MedImmune |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  | $ 27,500,000 |  |  |  |  |  | $ 27,500,000 |  |  |  |  |  |
Anticipated development and regulatory event based payment receivable milestones |  |  |  |  |  |  |  |  |  |  |  |  | $ 355,000,000 |
Anticipated commercial event based payment receivable milestones |  |  |  |  |  |  |  |  |  |  |  |  | 345,000,000 |
Number of additional products to be developed | product |  |  |  | 2 |  |  |  |  |  |  |  |  |  |
Milestone payment, revenue recognized |  |  |  |  |  | $ 7,000,000 |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  | 296,000 |  | 296,000 |
Accounts receivable |  |  |  |  |  |  |  |  |  |  | 2,400,000 |  | 2,400,000 |
Revenue under collaborative research and development arrangements |  |  |  |  |  |  |  |  |  |  |  | 344,000 |  | 14,900,000
Collaborative Arrangement, Product | Hoffman-La Roche |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  |
Full payment |  |  |  |  |  |  | $ 8,500,000 |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 | 6,100,000
Collaborative Arrangement, Product | Coalition for Epidemic Preparedness Innovations |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, funding to be received | $ 56,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, period to receive funding for research and development | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |
Funding received for research and development |  |  |  |  |  |  |  |  |  |  | 1,200,000 |  | 2,000,000 |
Deferred grant funding |  |  |  |  |  |  |  |  |  |  | 1,300,000 |  | 1,300,000 |
Collaborative Arrangement, Product | Defense Advanced Research Projects Agency (DARPA) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accounts receivable |  |  |  |  |  |  |  |  |  |  | 379,000 |  | 379,000 |
Funding received for research and development |  |  |  |  |  |  |  |  |  |  | 140,000 | $ 1,400,000 | 1,000,000 | $ 9,100,000
Deferred grant funding |  |  |  |  |  |  |  |  |  |  | 99,000 |  | 99,000 |
Base award |  |  |  |  |  |  |  |  | $ 19,600,000 |  |  |  |  |
Option award |  |  |  |  |  |  |  |  | $ 24,600,000 |  |  |  |  |
Total funding received for research and development |  |  |  |  |  |  |  |  |  |  | $ 43,700,000 |  | $ 43,700,000 |
Foreign Tax Authority | Collaborative Arrangement, Product | ApolloBio |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign corporate income taxes reducing upfront payment |  |  |  |  | 2,200,000 |  |  |  |  |  |  |  |  |
Foreign non-corporate income taxes reducing upfront payment |  |  |  |  | $ 1,400,000 |  |  |  |  |  |  |  |  |

X
- Definition Collaboration Agreement, Additional Revenue To Be Achieved + References No definition available. + Details
Name: | ino_CollaborationAgreementAdditionalRevenueToBeAchieved
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones + References No definition available. + Details
Name: | ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones + References No definition available. + Details
Name: | ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreement, Royalty Period + References No definition available. + Details
Name: | ino_CollaborationAgreementRoyaltyPeriod
Namespace Prefix: | ino_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Agreement, Territory Expansion Option Period + References No definition available. + Details
Name: | ino_CollaborationAgreementTerritoryExpansionOptionPeriod
Namespace Prefix: | ino_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreement, Advisory Fees + References No definition available. + Details
Name: | ino_CollaborativeAgreementAdvisoryFees
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Agreement, Base Award + References No definition available. + Details
Name: | ino_CollaborativeAgreementBaseAward
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreement, Corporate Income Tax + References No definition available. + Details
Name: | ino_CollaborativeAgreementCorporateIncomeTax
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreement, Non-Income Taxes + References No definition available. + Details
Name: | ino_CollaborativeAgreementForeignNonIncomeTaxes
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreement, Funding Received + References No definition available. + Details
Name: | ino_CollaborativeAgreementFundingReceived
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreeement, Funding Received for Research and Development + References No definition available. + Details
Name: | ino_CollaborativeAgreementFundingToBeReceived
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreement, Milestone Payment, Revenue Recognized + References No definition available. + Details
Name: | ino_CollaborativeAgreementMilestonePaymentRevenueRecognized
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Agreement, Number of Days Written Notice Before Termination + References No definition available. + Details
Name: | ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination
Namespace Prefix: | ino_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreement, Option Award + References No definition available. + Details
Name: | ino_CollaborativeAgreementOptionAward
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreement, Period From Effective Date For Termination + References No definition available. + Details
Name: | ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination
Namespace Prefix: | ino_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreement, Period to Receive Funding for Research and Development + References No definition available. + Details
Name: | ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment
Namespace Prefix: | ino_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreement, Proceeds From Contract Termination + References No definition available. + Details
Name: | ino_CollaborativeAgreementProceedsFromContractTermination
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreement, Total Funding Received + References No definition available. + Details
Name: | ino_CollaborativeAgreementTotalFundingReceived
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Agreements, Upfront Payment Received + References No definition available. + Details
Name: | ino_CollaborativeAgreementsUpfrontPaymentReceived
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Deferred Grant Funding, Current + References No definition available. + Details
Name: | ino_DeferredGrantFundingCurrent
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number Of Additional Products + References No definition available. + Details
Name: | ino_NumberOfAdditionalProducts
Namespace Prefix: | ino_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Proceeds From Collaborative Agreement + References No definition available. + Details
Name: | ino_ProceedsFromCollaborativeAgreement
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue Under Collaborative Research and Development Arrangements + References No definition available. + Details
Name: | ino_RevenueUnderCollaborativeResearchandDevelopmentArrangements
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=ino_ApolloBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ino_MedImmuneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementProductAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ino_HoffmanLaRocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ino_DefenseAdvancedResearchProjectsAgencyDARPAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |